BCIQ Profiles

Company Profile Report

AGR2 and LYPD3 as breast cancer targets

DISEASE CATEGORY: Cancer

INDICATION: Breast cancer

Inhibiting the membrane receptor LYPD3 or its ligand AGR2 could treat endocrine therapy-resistant breast

Read the full 182 word article

How to gain access

Continue reading with a
two-week free trial.